Synovus Financial’s Sage Therapeutics SAGE Stock Holding History

Synovus Financial’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-41	Closed	-$2K	–	1299
2020 Q2	$2K	Sell	41 -12	-23%	-$436	﹤0.01%	1440
2020 Q1	$1K	Buy	53 +12	+29%	+$695	﹤0.01%	2066
2019 Q4	$3K	Hold	41	–	–	﹤0.01%	1390
2019 Q3	$6K	Hold	41	–	–	﹤0.01%	1266
2019 Q2	$8K	Hold	41	–	–	﹤0.01%	1161
2019 Q1	$7K	Hold	41	–	–	﹤0.01%	1177
2018 Q4	$4K	Hold	41	–	–	﹤0.01%	1236
2018 Q3	$6K	Buy	+41	New	+$6.33K	﹤0.01%	1211

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Synovus Financial's SAGE Position: Q3 2020 in Review

Synovus Financial sold out of Sage Therapeutics (SAGE) in Q3 2020, closing a stake of 41 shares — an estimated $2K sold.

Synovus Financial first reported a position in SAGE in Q3 2018 and held it in 8 quarters. The position peaked at $8K in Q2 2019. 231 funds tracked by Wall St. Rank hold SAGE as of Q3 2020.

Synovus Financial reported no remaining Sage Therapeutics position as of Q3 2020 after selling out during the quarter.
Synovus Financial sold 41 Sage Therapeutics shares in Q3 2020, an estimated $2K.
Synovus Financial first reported a position in Sage Therapeutics in Q3 2018 and held it in 8 quarters.
Synovus Financial's Sage Therapeutics position peaked at $8K in Q2 2019.
231 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.